CompletedPhase 2ACTRN12605000001695
A phase II trial of gemcitabine in a fixed dose rate infusion combined with cisplatin in patients with operable biliary tract carcinomas
A phase II trial of gemcitabine in a fixed dose rate infusion combined with cisplatin in patients with operable biliary tract carcinomas with the primary objective tumour response
Sponsor
AGITG/ NHMRC Clinical Trials Centre
Enrollment
45 participants
Start Date
Feb 1, 2005
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and females
Inclusion Criteria1
- Histologic or cytologic diagnosis of adenocarcinogen of the gallbladder or intra/extrahepatic bile ducts with locally advanced or metastatic disease that is not amenable to curative surgical resection or with recurrent disease after prior surgical resection or radiotherapy. Measurable disease.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Gemcitabine delivered as fixed dose-rate infusion with cisplatin
Gemcitabine delivered as fixed dose-rate infusion with cisplatin
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000001695